Impact of hepatitis C virus (HCV) genotypes on quantification of HCV RNA in serum by COBAS AmpliPrep/COBAS TaqMan HCV test, Abbott antiretroviral therapy HCV RealTime assay, and VERSANT HCV RNA assay

Journal of Clinical Microbiology

Volumn 45, Issue 9, 2007, Pages 3077-3081

  Tuaillon, Edouard ^a   Mondain, Anne Marie ^a   Ottomani, Laure ^a   Roudière, Laurent ^a   Perney, Pascal ^b   Picot, Marie Christine ^c   Séguret, Fabienne ^c   Blanc, François ^b   Larrey, Dominique ^b   Van De Perre, Philippe ^a   Ducos, Jacques ^a  

^a LAPEYRONIE HOSPITAL   (France)

^b HÔPITAL SAINT ELOI   (France)

^c HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ARTICLE; BLOOD LEVEL; DEVICE; GENOTYPE; HEPATITIS C VIRUS; INTERMETHOD COMPARISON; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RNA ANALYSIS;

HEPACIVIRUS; HEPATITIS C; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; REAGENT KITS, DIAGNOSTIC; RNA, VIRAL; SERUM; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 34548702200     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00111-07     Document Type: Article

References (17)

1. Armitage, P., G. Berry, and J. N. S. Matthews. 2002. Statistical methods in medical research. Blackwell Science, Oxford, Malden, MA.
2. Berg, T., C. Sarrazin, E. Herrmann, H. Hinrichsen, T. Gerlach, R. Zachoval, B. Wiedenmann, U. Hopf, and S. Zeuzem. 2003. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37:600-609.
3. Bland, J. M., and D. G. Altman. 1986. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet i:307-310.
4. Caliendo, A. M., A. Valsamakis, Y. Zhou, B. Yen-Lieberman, J. Andersen, S. Young, A. Ferreira-Gonzalez, G. J. Tsongalis, R. Pyles, J. W. Bremer, and N. S. Lurain. 2006. Multilaboratory comparison of hepatitis C virus viral load assays. J. Clin. Microbiol. 44:1726-1732.
5. Davis, G. L. 2003. New approaches and therapeutic modalities for the prevention and treatment of recurrent HCV after liver transplantation. Liver Transpl. 9:S114-S119.
6. Forns, X., and J. Costa. 2006. HCV virological assessment. J. Hepatol. 44:S35-S39.
7. Fried, M. W., M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Goncales, Jr., D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, and J. Yu. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
8. Gallegos-Orozco, J. F., A. P. Fuentes, M. A. Olivera-Martinez, G. Gutierrez-Reyes, D. Cortina, J. A. Oregel, C. Perez-Pruna, M. S. Sixtos, S. Cruz-Castellanos, L. E. Soto-Ramirez, R. Rodriguez-Diaz, L. Fuentes-Romero, M. C. Gutierrez-Ruiz, and D. Kershenobich. 2003. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin. Rev. Investig. Clin. 55:138-142.
9. Hadziyannis, S. J., H. Sette, Jr., T. R. Morgan, V. Balan, M. Diago, P. Marcellin, G. Ramadori, H. Bodenheimer, Jr., D. Bernstein, M. Rizzetto, S. Zeuzem, P. J. Pockros, A. Lin, and A. M. Ackrill. 2004. Peginterferon- alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140:346-355.
10. Halfon, P., G. Penaranda, M. Bourliere, H. Khiri, M. F. Masseyeff, and D. Ouzan. 2006. Assessment of early virological response to antiviral therapy by comparing four assays for HCV RNA quantification using the international unit standard: implications for clinical management of patients with chronic hepatitis C virus infection. J. Med. Virol. 78:208-215.
11. Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M. Ling, and J. K. Albrecht. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
12. NIH. 2002. NIH consensus statement on management of hepatitis C. NIH Consens. State Sci. Statements 19:1-46.
13. Sarrazin, C., B. C. Gartner, D. Sizmann, R. Babiel, U. Mihm, W. P. Hofmann, M. von Wagner, and S. Zeuzem. 2006. Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. J. Clin. Microbiol. 44:729-737.
14. Simmonds, P., J. Bukh, C. Combet, G. Deleage, N. Enomoto, S. Feinstone, P. Halfon, G. Inchauspe, C. Kuiken, G. Maertens, M. Mizokami, D. G. Murphy, H. Okamoto, J. M. Pawlotsky, F. Penin, E. Sablon, I. T. Shin, L. J. Stuyver, H. J. Thiel, S. Viazov, A. J. Weiner, and A. Widell. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962-973.
15. Terrault, N. A., J. M. Pawlotsky, J. McHutchison, F. Anderson, M. Krajden, S. Gordon, I. Zitron, R. Perrillo, R. Gish, M. Holodniy, and M. Friesenhahn. 2005. Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy. J. Viral Hepat. 12:465-472.
16. von Wagner, M., M. Huber, T. Berg, H. Hinrichsen, J. Rasenack, T. Heintges, A. Bergk, C. Bernsmeier, D. Haussinger, E. Herrmann, and S. Zeuzem. 2005. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129:522-527.
17. Zeuzem, S., J. M. Pawlotsky, E. Lukasiewicz, M. von Wagner, I. Goulis, Y. Lurie, E. Gianfranco, J. M. Vrolijk, J. I. Esteban, C. Hezode, M. Lagging, F. Negro, A. Soulier, E. Verheij-Hart, B. Hansen, R. Tal, C. Ferrari, S. W. Schalm, and A. U. Neumann. 2005. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J. Hepatol. 43:250-257.